该研究是一项全球随机、双盲、安慰剂对照研究，评估了Cyramza联合erlotinib（厄洛替尼）相对于安慰剂联合erlotinib一线治疗既往未接受治疗的转移性 ...

Erlotinib (Tarceva™, OSI-774), a potent epidermal growth factor receptor tyrosine kinase inhibitor (EGFR), was evaluated in a phase II study to assess its activity in patients with metastatic ...

This article will describe the development of erlotinib, an EGFR tyrosine kinase inhibitor (EGFR-TKI), focusing on the clinical data reported in the treatment of NSCLC.

Erlotinib, an epidermal growth factor receptor inhibitor, is subject to multiple drug-drug interactions.Erlotinib (Tarceva; Genentech, Astellas) is approved for treatment of advanced or metastatic ...

Another study showed greater than 20% 6-month progression-free survival (PFS) in recurrent GBM after erlotinib treatment. 11 Another study noted erlotinib activity in particular in GBM with combined ...

Consolidation therapy with erlotinib plus bevacizumab could not be delivered in the majority of our patients, whereas this regimen was shown to be well tolerated in refractory advanced NSCLC. 32, 33 ...

"Erlotinib in combination with gemcitabine is a step forward, but I do not believe this is the answer to pancreatic cancer," Dr. Saif commented.

Loss of heterozygosity predicted increased risk for oral cancer among patients with oral premalignant lesions, according to the results of a randomized clinical trial.Although loss of ...

At the time of the manufacturer's original evidence submission, the marketing authorisation for erlotinib had not been granted and the population who would be covered by the marketing authorisation ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of maintenance treatment with erlotinib, having considered evidence on the nature of non-small-cell lung ...

Therefore, erlotinib was again discontinued, and we administered 125 mg of aprepitant on day 1 after discontinuation and 80 mg of aprepitant on days 2 and 3, with the aim of treating the pruritus.